Valuation : Axogen, Inc.

Market Cap 2.53B 2.18B 2.05B 1.87B 3.5B 239B 3.51B 24.23B 9.4B 123B 9.51B 9.3B 395B P/E 2026 *
-112x
P/E 2027 * 471x
Enterprise Value 2.53B 2.18B 2.05B 1.87B 3.5B 239B 3.51B 24.23B 9.4B 123B 9.51B 9.3B 395B EV / Sales 2026 *
9.06x
EV / Sales 2027 * 7.65x
Free-Float
97.38%
Yield 2026 *
-
Yield 2027 * -
1 day+2.49%
1 week-6.45%
Current month-5.14%
1 month+4.77%
3 months+13.59%
6 months+64.78%
Current year+47.11%
1 week 46.29
Extreme 46.29
51.5
1 month 44.11
Extreme 44.11
52.91
Current year 27.54
Extreme 27.54
52.91
1 year 15.27
Extreme 15.2701
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 09/08/2024
Director of Finance/CFO 42 12/05/2025
Chief Operating Officer 65 10/01/2025
Director TitleAgeSince
Director/Board Member 65 01/09/2016
Director/Board Member 58 15/05/2019
Chairman 70 09/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/26 Exercice

Director

40,059 0.0745%
10/08/26 Exercice

Compliance Officer

202,500 0.3767%
07/08/26 Sell

Director

-14,150 0.0263%
Change 5-day change 1-year change 3-year change Capi.($)
+2.56%-6.45%+212.66%+682.93% 2.53B
-0.86%-1.35%+25.39%+13.24% 229B
-1.67%-4.03%+4.19%-20.51% 148B
-1.08%-1.74%-19.45%+18.99% 131B
+1.80%+1.89%-55.52%-10.46% 68.04B
+0.17%-0.47%+10.91%+18.19% 51.75B
+0.49%-1.32%-17.27%-14.42% 50.21B
+0.87%-1.62%+17.80%+27.47% 42.28B
-0.84%-1.03%+36.95%+48.52% 40.63B
-0.70%-5.32%-16.89%+47.87% 33.06B
Average +0.08%-2.11%+19.88%+81.18% 79.62B
Weighted average by Cap. -0.56%-1.81%+2.56%+10.57%

Financials

2026 *2027 *
Net sales 280M 241M 226M 207M 387M 26.4B 388M 2.67B 1.04B 13.54B 1.05B 1.03B 43.63B 331M 285M 268M 245M 458M 31.26B 459M 3.17B 1.23B 16.04B 1.24B 1.22B 51.66B
Net income -22.88M -19.69M -18.53M -16.92M -31.66M -2.16B -31.75M -219M -84.96M -1.11B -85.93M -84.06M -3.57B 4.76M 4.1M 3.86M 3.52M 6.59M 450M 6.61M 45.55M 17.68M 231M 17.88M 17.49M 743M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
04/09/26 $48.23 +2.40% 227,095
03/09/26 $47.10 -2.48% 951,253
02/09/26 $48.30 -3.17% 789,915
01/09/26 $49.88 -1.73% 596,566
31/08/26 $50.76 -1.38% 878,137
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
47.10USD
Average target price
53.90USD
Spread / Average Target
+14.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock